<DOC>
	<DOCNO>NCT00550043</DOCNO>
	<brief_summary>The purpose study understand safety tolerability INCB018424 patient rheumatoid arthritis</brief_summary>
	<brief_title>A Study Exploring Safety , Tolerability Efficacy 4 Week Course INCB018424 Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Established diagnosis rheumatoid arthritis 2 . Patients receive methotrexate must treat least 6 month receive stable weekly dose 10 25 mg least 8 consecutive week prior study entry . 1 . Patients take follow drug within timeframe : Leflunomide , infliximab , etanercept , adalimumab , abatacept , biological therapy ( except rituximab ) Within 12 week prior first dose study medication ; Rituximab Within 12 month prior first dose study medication ; Diseasemodifying antirheumatic drug ( DMARDs ) antirheumatic therapy specify include limited : gold , penicillamine , dapsone , azathioprine , 6mercaptopurine , chlorambucil , cyclophosphamide , cyclosporin , mycophenolate mofetil Within 12 week prior first dose study medication ; 2 . Treatment investigational medication within 12 week prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>